

Sprycel 20mg belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel, are BCRABL, SRC, Ephrin’s and GFR.




Sprycel 20mg belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel, are BCRABL, SRC, Ephrin’s and GFR.

